Bioeq
Biosimilar developer, Switzerland. 1 development product across 1 molecule: ranibizumab.
First approval in the Atlas: Aug 2022, Cimerli, ranibizumab (FDA)
FDAproducts approved1
EMAproducts approved1
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Ranibizumab | Cimerli / Ranivisio FYB201 | Aug 2022 | Aug 2022 | · | · | · | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- FDAAug 2022Cimerli, ranibizumab
- EMAAug 2022Ranivisio, ranibizumab
- EMASep 2024Epruvy, ranibizumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.